Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Nicotine | The risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Nicotine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Mecamylamine. |
| Pentolinium | The risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Pentolinium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Trimethaphan. |
| Hexamethonium | The risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Hexamethonium. |
| Cyclopentamine | The risk or severity of adverse effects can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Cyclopentamine. |
| Methotrexate | The protein binding of Methotrexate can be increased when combined with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Ketoprofen | The risk or severity of adverse effects can be increased when Ketoprofen is combined with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Dexketoprofen | The risk or severity of adverse effects can be increased when Dexketoprofen is combined with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Cyclosporine | The risk or severity of renal failure can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Cyclosporine. |
| Insulin human | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin human. |
| Insulin lispro | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin lispro. |
| Insulin glargine | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin glargine. |
| Insulin pork | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin pork. |
| Troglitazone | The therapeutic efficacy of Troglitazone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Sulfisoxazole | The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Disopyramide | The therapeutic efficacy of Disopyramide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Acarbose | The therapeutic efficacy of Acarbose can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Metformin | The therapeutic efficacy of Metformin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Sulfadiazine | The therapeutic efficacy of Sulfadiazine can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Rosiglitazone | The therapeutic efficacy of Rosiglitazone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Quinine | The therapeutic efficacy of Quinine can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Miglitol | The therapeutic efficacy of Miglitol can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Nateglinide | The therapeutic efficacy of Nateglinide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Pentamidine | The therapeutic efficacy of Pentamidine can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Mifepristone | The therapeutic efficacy of Mifepristone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Tolazamide | The therapeutic efficacy of Tolazamide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Repaglinide | The therapeutic efficacy of Repaglinide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Phenformin | The therapeutic efficacy of Phenformin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Sulfamethoxazole | The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Glyburide | The therapeutic efficacy of Glyburide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Glipizide | The therapeutic efficacy of Glipizide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Gliclazide | The therapeutic efficacy of Gliclazide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Pioglitazone | The therapeutic efficacy of Pioglitazone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Bromocriptine | The therapeutic efficacy of Bromocriptine can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Gliquidone | The therapeutic efficacy of Gliquidone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Mitiglinide | The therapeutic efficacy of Mitiglinide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Sitagliptin | The therapeutic efficacy of Sitagliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Sunitinib | The therapeutic efficacy of Sunitinib can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Exenatide | The therapeutic efficacy of Exenatide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Mecasermin | The therapeutic efficacy of Mecasermin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Pramlintide | The therapeutic efficacy of Pramlintide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Glisoxepide | The therapeutic efficacy of Glisoxepide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Insulin aspart | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin aspart. |
| Insulin detemir | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin detemir. |
| Insulin glulisine | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin glulisine. |
| Glymidine | The therapeutic efficacy of Glymidine can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| AICA ribonucleotide | The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Buformin | The therapeutic efficacy of Buformin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Voglibose | The therapeutic efficacy of Voglibose can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| NN344 | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with NN344. |
| AMG-222 | The therapeutic efficacy of AMG-222 can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Bisegliptin | The therapeutic efficacy of Bisegliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Alogliptin | The therapeutic efficacy of Alogliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Dapagliflozin | The therapeutic efficacy of Dapagliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Saxagliptin | The therapeutic efficacy of Saxagliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Liraglutide | The therapeutic efficacy of Liraglutide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Gosogliptin | The therapeutic efficacy of Gosogliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Linagliptin | The therapeutic efficacy of Linagliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Canagliflozin | The therapeutic efficacy of Canagliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Glibornuride | The therapeutic efficacy of Glibornuride can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Benfluorex | The therapeutic efficacy of Benfluorex can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Empagliflozin | The therapeutic efficacy of Empagliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Albiglutide | The therapeutic efficacy of Albiglutide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Dulaglutide | The therapeutic efficacy of Dulaglutide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Lobeglitazone | The therapeutic efficacy of Lobeglitazone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Netoglitazone | The therapeutic efficacy of Netoglitazone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Rivoglitazone | The therapeutic efficacy of Rivoglitazone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Ciglitazone | The therapeutic efficacy of Ciglitazone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Lixisenatide | The therapeutic efficacy of Lixisenatide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Insulin beef | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin beef. |
| Insulin degludec | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin degludec. |
| Insulin peglispro | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin peglispro. |
| Insulin tregopil | The risk or severity of hypoglycemia can be increased when 5-(2-methylpiperazine-1-sulfonyl)isoquinoline is combined with Insulin tregopil. |
| Ipragliflozin | The therapeutic efficacy of Ipragliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Dutogliptin | The therapeutic efficacy of Dutogliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Allicin | The therapeutic efficacy of Allicin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Tofogliflozin | The therapeutic efficacy of Tofogliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Ertugliflozin | The therapeutic efficacy of Ertugliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| 2,4-thiazolidinedione | The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Teneligliptin | The therapeutic efficacy of Teneligliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Omarigliptin | The therapeutic efficacy of Omarigliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Carmegliptin | The therapeutic efficacy of Carmegliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Gemigliptin | The therapeutic efficacy of Gemigliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Anagliptin | The therapeutic efficacy of Anagliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Evogliptin | The therapeutic efficacy of Evogliptin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Sotagliflozin | The therapeutic efficacy of Sotagliflozin can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Balaglitazone | The therapeutic efficacy of Balaglitazone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Remogliflozin etabonate | The therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Carbutamide | The therapeutic efficacy of Carbutamide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Guar gum | The therapeutic efficacy of Guar gum can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Metahexamide | The therapeutic efficacy of Metahexamide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Semaglutide | The therapeutic efficacy of Semaglutide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Taspoglutide | The therapeutic efficacy of Taspoglutide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |
| Englitazone | The therapeutic efficacy of Englitazone can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline. |